News Conference News AHA 2022 BRIGHT-4: Large, ‘Clean’ Trial Clarifies Bivalirudin Benefits in STEMI Shelley Wood November 06, 2022
News Daily News Still No Edge for Bivalirudin in VALIDATE-SWEDEHEART’s STEMI Patients Shelley Wood December 22, 2021
News Conference News TCT 2020 Bivalirudin vs Heparin Patient-Level Meta-analysis Stirs an Old Debate Shelley Wood October 14, 2020
News Conference News CRT 2018 Radial Access PCI Reduces Risk of Mortality and Bleeding in VALIDATE-SWEDEHEART Michael O'Riordan March 06, 2018
Presentation TCT 2017 VALIDATE-SWEDEHEART NSTEMI: A Randomized Trial of Bivalirudin vs Heparin Monotherapy in Patients With NSTEMI Presenter: Thomas F. Luscher, David Erlinge October 31, 2017
Presentation TCT 2017 VALIDATE-SWEDEHEART STEMI: A Randomized Trial of Bivalirudin vs Heparin Monotherapy in Patients With STEMI Presenter: Y. S. Chandrashekhar, David J. Moliterno, Stefan K. James October 31, 2017
News Opinion Editor's Corner ESC 2017 My Takeaways From ESC 2017: That Lovin’ Feeling? Barcelona Brings It Back Shelley Wood September 08, 2017
News Conference News ESC 2017 Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART Shelley Wood August 27, 2017
Presentation ESC 2017 Bivalirudin vs Heparin Monotherapy in Myocardial Infarction:The VALIDATE-SWEDEHEART Trial Presenter: David Erlinge August 27, 2017
News Daily News SCAAR: Stent Thrombosis Risk After Primary PCI No Higher With Bivalirudin Than Other Antithrombotics Todd Neale February 19, 2015